Sulfinpyrazone
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.
![]() | |
Clinical data | |
---|---|
Trade names | Apo-sulfinpyrazone |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682339 |
Routes of administration | oral intravenous |
ATC code |
|
Pharmacokinetic data | |
Protein binding | 98–99% |
Metabolism | hepatic |
Excretion | renal |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.325 ![]() |
Chemical and physical data | |
Formula | C23H20N2O3S |
Molar mass | 404.48 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.
Contraindications
Sulfinpyrazone must not be used in persons with renal impairment or a history of uric acid kidney stones.[1]
References
- Underwood M (June 2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.